Home | Welcome to Contract Pharma   
Last Updated Friday, October 24 2014
Print

Synergy Completes Callisto Merger



Published January 18, 2013
Synergy Pharmaceuticals, a drug developer focused on gastrointestinal disorders and diseases, has concluded its merger with Callisto Pharmaceuticals, a biotechnology company that develops novel therapeutics to treat cancer.
 
Under the terms of the merger agreement, each outstanding share of Callisto common stock was converted into one share of Synergy common stock and the approximately 22.3 million shares of Synergy held by Callisto were canceled. Callisto's common stock will no longer be traded on the OTC QB.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On